SOLAR 3D: Wk 48 Results of Switching to DTG/3TC From Suppressive 3- or 4-Drug ART in PWH With M184V/I Mutations and Virologic Failure

October 27-30, 2021; London, United Kingdom
In open-label study, 2-drug regimen was found to be safe and effective at maintaining virologic suppression in patients with multiple previous virologic failures and historic or current M184V/I.
Format: Microsoft PowerPoint (.ppt)
File Size: 183 KB
Released: November 2, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

CCO presenta a la Dra. Leticia M. Pérez Saleme explicando los factores principales a tomar en cuenta cuando se toman decisiones basadas en evidencia para optimizar el TAR en pacientes con supresión virológica en México

Leticia M. Pérez Saleme, MD Released: February 17, 2022

Slides from Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 14, 2022

Dr Jason Schafer and Clinical Care Options (CCO): Antiretroviral stewardship can address key considerations for ART in the inpatient setting.

person default Jason Schafer, PharmD, MPH Released: February 7, 2022

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

Prof Gail Matthews, MD, PhD Released: January 25, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings